8.94
0.45%
-0.04
After Hours:
8.94
Shattuck Labs Inc stock is currently priced at $8.94, with a 24-hour trading volume of 319.07K.
It has seen a -0.45% decreased in the last 24 hours and a -0.56% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $9.02 pivot point. If it approaches the $8.70 support level, significant changes may occur.
Shattuck Labs Inc Stock (STTK) Financials Data
Shattuck Labs Inc (STTK) Revenue 2023
STTK reported a revenue (TTM) of $1.66 million for the quarter ending December 31, 2023, a -94.48% decline year-over-year.
Shattuck Labs Inc (STTK) Net Income 2023
STTK net income (TTM) was -$87.30 million for the quarter ending December 31, 2023, a +14.37% increase year-over-year.
Shattuck Labs Inc (STTK) Cash Flow 2023
STTK recorded a free cash flow (TTM) of -$81.64 million for the quarter ending December 31, 2023, a +23.07% increase year-over-year.
Shattuck Labs Inc (STTK) Earnings per Share 2023
STTK earnings per share (TTM) was -$2.05 for the quarter ending December 31, 2023, a +14.94% growth year-over-year.
Shattuck Labs Inc Stock (STTK) Latest News
Shattuck Labs Announces Participation in Upcoming March Conferences
GlobeNewswire Inc.
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
GlobeNewswire Inc.
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
Benzinga
Dow Jumps Over 200 Points; Federal Reserve Holds Interest Rates Steady
Benzinga
About Shattuck Labs Inc
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Cap:
|
Volume (24h):